Kura Oncology's Ziftomenib Approval Receives Positive Reactions from Barclays and the FDA
AI Summary1 min read
TL;DR
Kura Oncology's stock is projected to double by 2026 after Barclays raised its price target to $28, driven by the FDA approval of ziftomenib for acute myeloid leukemia based on positive trial results.
Tags
Kura OncologyziftomenibFDA approvalBarclaysacute myeloid leukemia
Kura Oncology (KURA) stock is expected to double in 2026 after Barclays analyst Etzer Darout raised the price target to $28 from $11 and maintained an Overweight rating. The approval of ziftomenib, a treatment for relapsed or refractory acute myeloid leukemia, is seen as a significant factor in this prediction. The approval was based on data from the pivotal KOMET-001 trial, which demonstrated compelling efficacy and a favorable safety profile.
